These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 33769194)
1. Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1. Raju B; Verma H; Narendra G; Sapra B; Silakari O J Biomol Struct Dyn; 2022 Oct; 40(17):7975-7990. PubMed ID: 33769194 [TBL] [Abstract][Full Text] [Related]
2. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations. Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064 [TBL] [Abstract][Full Text] [Related]
3. In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study. Sharma H; Raju B; Narendra G; Kumar M; Verma H; Sharma B; Tung GK; Kumar Jain S; Brás NF; Silakari O J Mol Graph Model; 2023 Mar; 119():108390. PubMed ID: 36502606 [TBL] [Abstract][Full Text] [Related]
4. Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from MetaSite, molecular docking and quantum chemical calculations. Pragyan P; Kesharwani SS; Nandekar PP; Rathod V; Sangamwar AT Mol Divers; 2014 Nov; 18(4):865-78. PubMed ID: 25028215 [TBL] [Abstract][Full Text] [Related]
5. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations. Kumar R; Gupta D Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691 [TBL] [Abstract][Full Text] [Related]
6. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468 [TBL] [Abstract][Full Text] [Related]
7. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs. Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468 [TBL] [Abstract][Full Text] [Related]
8. Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells. Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB J Chem Inf Model; 2017 Jun; 57(6):1309-1320. PubMed ID: 28489395 [TBL] [Abstract][Full Text] [Related]
10. A new class of CYP1B1 inhibitors derived from bentranil. Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors. Wierzchowski M; Dutkiewicz Z; Gielara-Korzańska A; Korzański A; Teubert A; Teżyk A; Stefański T; Baer-Dubowska W; Mikstacka R Chem Biol Drug Des; 2017 Dec; 90(6):1226-1236. PubMed ID: 28632937 [TBL] [Abstract][Full Text] [Related]
13. Multiple machine learning models combined with virtual screening and molecular docking to identify selective human ALDH1A1 inhibitors. Narendra G; Raju B; Verma H; Sapra B; Silakari O J Mol Graph Model; 2021 Sep; 107():107950. PubMed ID: 34089986 [TBL] [Abstract][Full Text] [Related]
14. Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations. Dutkiewicz Z; Mikstacka R Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511239 [TBL] [Abstract][Full Text] [Related]
15. Identification of potential histone deacetylase1 (HDAC1) inhibitors using multistep virtual screening approach including SVM model, pharmacophore modeling, molecular docking and biological evaluation. Krishna S; Lakra AD; Shukla N; Khan S; Mishra DP; Ahmed S; Siddiqi MI J Biomol Struct Dyn; 2020 Jul; 38(11):3280-3295. PubMed ID: 31411124 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study. Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993 [TBL] [Abstract][Full Text] [Related]
17. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1. Jerabek P; Martinek V; Stiborova M Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840 [TBL] [Abstract][Full Text] [Related]
18. Nitidine Chloride-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism. Mao X; Wang J; Wang Q; Yang L; Li Y; Lin H; Peng Y; Zheng J Drug Metab Dispos; 2019 Aug; 47(8):919-927. PubMed ID: 31147316 [TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression. Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]